Kiniksa Pharmaceuticals Reports Q1 2026 Financial Results
Summary
Kiniksa Pharmaceuticals International, plc filed a Form 8-K current report with the SEC on April 28, 2026, reporting financial results for the first quarter of 2026. The filing discloses Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), with supporting exhibit EX-99.1 attached. The company, headquartered at 105 Piccadilly, Second Floor, London, is a biopharmaceutical firm operating in the pharmaceutical preparations industry (SIC 2834) with EIN 981795578 and CIK 0001730430.
About this source
GovPing monitors SEC EDGAR - Form 8-K Filings for new securities & markets regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.
What changed
Kiniksa Pharmaceuticals International, plc submitted a Form 8-K current report to the SEC on April 28, 2026 (Accession No. 0001730430-26-000017). The filing covers Item 2.02 (Results of Operations and Financial Condition), reporting the company's financial performance for Q1 2026, and Item 9.01 (Financial Statements and Exhibits), with exhibit EX-99.1 providing detailed financial statements.
Public companies, investors, and financial analysts should note that this is a routine quarterly disclosure under SEC reporting requirements. Kiniksa is a biopharmaceutical company (SIC 2834) incorporated in the UK (105 Piccadilly, London W1J 7NJ) and registered with the SEC under File No. 001-38492.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Filing Detail
- SEC Home »
- Company Search »
- Current Page Form 8-K - Current report: SEC Accession No. 0001730430-26-000017 Filing Date 2026-04-28 Accepted 2026-04-28 07:32:20 Documents 13 Period of Report 2026-04-28 Items Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files
| Seq | Description | Document | Type | Size |
|---|---|---|---|---|
| 1 | 8-K | knsa-20260428x8k.htm iXBRL | 8-K | 41257 |
| 2 | EX-99.1 | knsa-20260428xex99d1.htm | EX-99.1 | 135691 |
| 3 | GRAPHIC | knsa-20260428xex99d1001.jpg | GRAPHIC | 9790 |
| Complete submission text file | 0001730430-26-000017.txt | 312022 |
Data Files
| Seq | Description | Document | Type | Size |
|---|---|---|---|---|
| 4 | EX-101.SCH | knsa-20260428.xsd | EX-101.SCH | 2666 |
| 5 | EX-101.LAB | knsa-20260428_lab.xml | EX-101.LAB | 15215 |
| 6 | EX-101.PRE | knsa-20260428_pre.xml | EX-101.PRE | 9627 |
| 16 | EXTRACTED XBRL INSTANCE DOCUMENT | knsa-20260428x8k_htm.xml | XML | 4688 |
| Mailing Address 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ Business Address 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ 7814319100 Kiniksa Pharmaceuticals International, plc (Filer) CIK: 0001730430 (see all company filings) EIN.: 981795578 | Fiscal Year End: 1231 | |||
| Type: 8-K | Act: 34 | File No.: 001-38492 | Film No.: 26903152 |
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)
Named provisions
Related changes
Get daily alerts for SEC EDGAR - Form 8-K Filings
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from SEC.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when SEC EDGAR - Form 8-K Filings publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.